Tags

Type your tag names separated by a space and hit enter

Antibiotic resistance surveillance over a 4-year period (2000-2003) in Turkey: results of the MYSTIC Program.
Diagn Microbiol Infect Dis. 2007 Dec; 59(4):453-7.DM

Abstract

The Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program is a global study that provides antimicrobial susceptibility data in centers prescribing meropenem. The activity of meropenem and 7 broad-spectrum antimicrobials have been examined against 5208 bacterial isolates from 9 Turkish centers between 2000 and 2003. Cumulative susceptibility rates against all species of Enterobacteriaceae combined were ranked as follows: meropenem (99.3%), imipenem (97.6%), cefepime (80.0%), piperacillin-tazobactam (73.6%), ceftazidime (70.3%), ciprofloxacin (70.1%), cefotaxime (66.9%), and tobramycin (67.2%). The production of extended-spectrum beta-lactamases (ESBLs) was detected in 48.7% of Klebsiella pneumoniae and in 19.5% of Escherichia coli isolates. Of ESBL producing K. pneumoniae isolates, 75.7% were resistant to tobramycin, 40.3% to ciprofloxacin, and 48.3% to piperacillin-tazobactam. Only piperacillin/tazobactam and carbapenems were active against more than 50% of Pseudomonas aeruginosa at the National Committee for Clinical Laboratory Standards-susceptible breakpoint, and the carbapenems were the most active compounds against Acinetobacter spp. These data confirm the continued potency of meropenem against Enterobacteriaceae in units where it is actively being prescribed.

Authors+Show Affiliations

Marmara University School of Medicine, Istanbul, Turkey. korten@tnn.netNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17888609

Citation

Korten, Volkan, et al. "Antibiotic Resistance Surveillance Over a 4-year Period (2000-2003) in Turkey: Results of the MYSTIC Program." Diagnostic Microbiology and Infectious Disease, vol. 59, no. 4, 2007, pp. 453-7.
Korten V, Ulusoy S, Zarakolu P, et al. Antibiotic resistance surveillance over a 4-year period (2000-2003) in Turkey: results of the MYSTIC Program. Diagn Microbiol Infect Dis. 2007;59(4):453-7.
Korten, V., Ulusoy, S., Zarakolu, P., & Mete, B. (2007). Antibiotic resistance surveillance over a 4-year period (2000-2003) in Turkey: results of the MYSTIC Program. Diagnostic Microbiology and Infectious Disease, 59(4), 453-7.
Korten V, et al. Antibiotic Resistance Surveillance Over a 4-year Period (2000-2003) in Turkey: Results of the MYSTIC Program. Diagn Microbiol Infect Dis. 2007;59(4):453-7. PubMed PMID: 17888609.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antibiotic resistance surveillance over a 4-year period (2000-2003) in Turkey: results of the MYSTIC Program. AU - Korten,Volkan, AU - Ulusoy,Sercan, AU - Zarakolu,Pinar, AU - Mete,Birgul, AU - ,, Y1 - 2007/09/21/ PY - 2007/03/05/received PY - 2007/06/19/revised PY - 2007/06/23/accepted PY - 2007/9/25/pubmed PY - 2008/6/19/medline PY - 2007/9/25/entrez SP - 453 EP - 7 JF - Diagnostic microbiology and infectious disease JO - Diagn. Microbiol. Infect. Dis. VL - 59 IS - 4 N2 - The Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program is a global study that provides antimicrobial susceptibility data in centers prescribing meropenem. The activity of meropenem and 7 broad-spectrum antimicrobials have been examined against 5208 bacterial isolates from 9 Turkish centers between 2000 and 2003. Cumulative susceptibility rates against all species of Enterobacteriaceae combined were ranked as follows: meropenem (99.3%), imipenem (97.6%), cefepime (80.0%), piperacillin-tazobactam (73.6%), ceftazidime (70.3%), ciprofloxacin (70.1%), cefotaxime (66.9%), and tobramycin (67.2%). The production of extended-spectrum beta-lactamases (ESBLs) was detected in 48.7% of Klebsiella pneumoniae and in 19.5% of Escherichia coli isolates. Of ESBL producing K. pneumoniae isolates, 75.7% were resistant to tobramycin, 40.3% to ciprofloxacin, and 48.3% to piperacillin-tazobactam. Only piperacillin/tazobactam and carbapenems were active against more than 50% of Pseudomonas aeruginosa at the National Committee for Clinical Laboratory Standards-susceptible breakpoint, and the carbapenems were the most active compounds against Acinetobacter spp. These data confirm the continued potency of meropenem against Enterobacteriaceae in units where it is actively being prescribed. SN - 0732-8893 UR - https://www.unboundmedicine.com/medline/citation/17888609/Antibiotic_resistance_surveillance_over_a_4_year_period__2000_2003__in_Turkey:_results_of_the_MYSTIC_Program_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0732-8893(07)00290-8 DB - PRIME DP - Unbound Medicine ER -